Application of neuromuscular blocking agents in frail patients

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100046222

Enrollment

Unknown

Registered

2021-05-11

Start date

2021-05-08

Completion date

Unknown

Last updated

2021-12-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Frailty

Interventions

Frailty (Cisatracurium):NO

Non-frailty(Cisatracurium):NO

Frailty(Rocuronium):NO

Non-frailty(Rocuronium):NO

Eligibility

Sex/Gender

All

Age

60 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1.Aged >= 60 years; 2.ASA I-III; 3.BMI <= 30kg/m^2; 4.Those who plan to undergo elective non-cardiovascular surgery; 5.Be willing to sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Severe preoperative liver dysfunction (Child C) and renal insufficiency; 2. Severe consciousness, cognitive impairment, delirium; 3. Patients with acute inflammation, severe infection and large amount of antibiotics; 4. Persons with limb motor dysfunction and unable to exercise independently; 5. Myasthenia gravis, muscular atrophy or other neuromuscular diseases; 6. Have allergic diseases or allergies to neuromuscular blockers, or have a family history of Malignant Hyperthermia Syndrome.

Design outcomes

Primary

Measure	Time frame
T1 values;Dosage of neuromuscular blocking agents ;	—

Secondary

Measure	Time frame
Blood pressure;Heart Rate;Oxygenation;	—

Countries

China

Contacts

Public ContactLiu Cunming

Jiangsu Province Hospital

1335587409@qq.com+86 13951890866

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026